IMTX — Immatics N.V.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1809196 ·
Last close
$9.38
Market Cap
$1.28B
52W High
$11.94
52W Low
$8.76
ADV30
595,113
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 7,612,000 | — | -66,064,000 | -57,814,000 | 543,264,000 | 301,332,000 | 87,463,000 |
| Dec 2025 | 19,761,000 | — | -38,881,000 | -35,698,000 | 562,337,000 | 345,918,000 | 78,238,000 |
| Sep 2025 | 5,187,000 | — | -54,633,000 | -50,545,000 | 518,557,000 | 334,922,000 | 101,878,000 |
| Jun 2025 | 4,737,000 | — | -53,127,000 | -70,348,000 | 567,302,000 | 256,635,000 | 102,728,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-176,626,000
Investing CF
$204,787,000
Financing CF
$97,353,000
CapEx
$-6,805,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-785,988,000
Inventory
—
Receivables
$6,881,000
ST Investments
$123,419,000
EBIT TTM
$-197,488,000
Pretax Income TTM
$-198,434,000
Interest Exp TTM
$946,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$37,296,000
EBITDA
$-203,930,000
Free Cash Flow
$-110,854,376
Enterprise Value
$843,505,280
Total Cash
$453,569,984
Total Debt
$15,081,000
Shares Out
136,673,161
Trailing EPS
$-1.97
Book Value
$4.21
ROE
-43.2%
ROA
-22.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,266,000 | -182,016,000 | -196,447,000 | 562,337,000 | 78,238,000 | — | -176,626,000 |
| Dec 2024 | 155,835,000 | -38,615,000 | 15,218,000 | 696,146,000 | 121,304,000 | — | -158,030,000 |
| Dec 2023 | 53,997,000 | -101,725,000 | -94,649,000 | 509,965,000 | 292,347,000 | — | 18,228,000 |
| Dec 2022 | 172,831,000 | 29,954,000 | 27,703,000 | 407,820,000 | 204,467,000 | — | 100,131,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.89
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $9.43 · call volume: 60 · put volume: 2Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $1.30B | $4.17 | — |
| DBVTF | DBV Technologies S.A. | $1.26B | $4.26 | — |
| MAZE | Maze Therapeutics, Inc. | $1.33B | $24.05 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.35B | $92.20 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.17B | $24.98 | — |
News headlines (Yahoo Finance, 1h cache)
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
2026-06-01 12:00 · Yahoo
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
2026-05-31 13:00 · Yahoo
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
2026-05-30 12:00 · Yahoo
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
2026-05-15 10:59 · Yahoo
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 12:25 · Yahoo
Immatics Announces First Quarter 2026 Financial Results and Business Update
2026-05-12 11:00 · Yahoo
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
2026-05-07 15:42 · Yahoo
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
2026-05-07 15:35 · Yahoo
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
2026-05-07 15:30 · Yahoo
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 15:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.